drugset / Trial / NCT05043324

Prevention and Treatment of Patient Before, During, and After Covid-19 Infection

NCT05043324 ↗

Phase 4 Completed 82 enrolled Nguyen Thi Trieu, MD
Non-randomizedParallel-groupQuadruple-blindTreatment

Summary

AntiCov-220 prevents and treats before, during, and after infection with SARS-CoV-2. The composition is fractionally extracted from herbs (Ascorbic Acid, L-Arginine hydrochloride, Adenosma glutinosum extract, Eclipta prostrata extract, Phyllanthus urinaria extract, Impatiens balsamina extract, Rutin, Pregnenolone acetate, Allium sativum, Pyridoxine 5-phosphate, Cyanocobalamin), using flavonoids, isoflavonoids, and pregnenolone in combination with ascorbic acid as the key compounds in preventing and killing SARS-CoV-2; increase antibodies and protect cells; supplementing precursors to help the body strengthen antibodies and reduce the risk of infection; destroy spike protein, toxic protein, help prevent blood clots causing stroke; restore the physiological function of cells after virus infection; helps the body to stabilize the amount of cortisol in the blood as well as stabilize the production of specific antibodies. The composition participates in anti-inflammatory and cell-protecting processes, bringing blood cortisol, B-lymphocytes, Cyfra 21-1, WBC, CRP, fever, dyspnea, and other signs of respiratory tract inflammation to a normal state and normal limit.

Timeline

Start
2020-02-20
Primary completion
2022-04-20
Completion
2022-04-27

Drugs

EvaluationDrugModalityDoseRoute
Subject AntiCov-220 Unknown — —

Indications